ReviewCancers2025

Characterizing Cardiotoxicity of FDA-Approved Soft Tissue Sarcoma Targeted Therapies and Immune Checkpoint Inhibitors: A Systematic Review.

Mustafa Houmsse et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.